CYTORECOVERY INC

CYTORECOVERY INC specializes in advanced biomedical research and development services, with a focus on cellular recovery technologies and bioanalytical innovation. The company leverages deep expertise in cell isolation, plasma fractionation, and high-throughput biomarker analysis to support next-generation therapeutic development. Their technical capabilities include proprietary microfluidic platforms, automated sample processing systems, and data-driven cell characterization workflows, enabling precise isolation and analysis of rare cellular populations. The firm’s differentiation lies in its integration of engineering principles with clinical translational science, delivering scalable solutions for complex biological samples under GMP-aligned conditions. Award history does not provide sufficient detail to identify specific federal agencies or programmatic relationships. Consequently, no confirmed agency engagements or recurring contract patterns can be inferred from available data. The primary NAICS code 541714 classifies CYTORECOVERY INC as a research and development firm in the life sciences, specifically in biotechnology research. In practice, this means the company engages in fundamental and applied research aimed at advancing diagnostic and therapeutic platforms, with an emphasis on cellular and molecular analysis. Their market positioning centers on niche biotech R&D services, serving entities requiring high-precision biological data generation and process optimization. CYTORECOVERY INC is structured as a small business (2L entity) headquartered in Blacksburg, Virginia. The company holds no federal certifications such as 8(a), HUBZone, or WOSB. Its geographic footprint is localized, with operations centered in Virginia’s research corridor, aligning it with regional academic and biotech ecosystems. The firm’s government market presence is defined by its technical specialization rather than broad contract volume, positioning it as a specialized R&D partner for complex biomedical challenges.